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What’s new? 
 Cohort studies to identify risk factors for foot ulceration in people with diabetes have 
been published in the biomedical literature since the early 1990s. 
 We assembled an international data set of risk factors collected from 16 385 
individuals with diabetes who took part in cohort studies to derive and validate a 
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prognostic model of three risk factors: a history of foot ulceration, an inability to feel 
a 10 g monofilament and at least one absent pedal pulse. 
 The use of only these three risk factors in foot risk assessments during annual diabetes 
foot checks could reduce the amount of time spent assessing risk and thereby increase 
the number of people with diabetes who have checks performed. 
 The frequency of risk assessment should be considered in future research. 
 
Abstract 
Aims Diabetes guidelines recommend screening for the risk of foot ulceration but vary 
substantially in the underlying evidence base. Our purpose was to derive and validate a 
prognostic model of independent risk factors for foot ulceration in diabetes using all available 
individual patient data from cohort studies conducted worldwide. 
Methods We conducted a systematic review and meta-analysis of individual patient data 
from 10 cohort studies of risk factors in the prediction of foot ulceration in diabetes. 
Predictors were selected for plausibility, availability and low heterogeneity. Logistic 
regression produced adjusted odds ratios (ORs) for foot ulceration by ulceration history, 
monofilament insensitivity, any absent pedal pulse, age, sex and diabetes duration. 
Results The 10 studies contained data from 16 385 participants. A history of foot ulceration 
produced the largest OR [6.59 (95% CI 2.49 to 17.45)], insensitivity to a 10 g monofilament 
[3.18 (95% CI 2.65 to 3.82)] and any absent pedal pulse [1.97 (95% CI 1.62 to 2.39)] were 
consistently, independently predictive. Combining three predictors produced sensitivities 
between 90.0% (95% CI 69.9% to 97.2%) and 95.3% (95% CI 84.5% to 98.7%); the 
corresponding specificities were between 12.1% (95% CI 8.2% to 17.3%) and 63.9% (95% 
CI 61.1% to 66.6%). 
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Conclusions This prognostic model of only three risk factors, a history of foot ulceration, an 
inability to feel a 10 g monofilament and the absence of any pedal pulse, compares 
favourably with more complex approaches to foot risk assessment recommended in clinical 
diabetes guidelines. 
 
<H1>Background 
Diabetes-related lower extremity amputations and foot ulcers cause considerable morbidity, 
more than double the rate of mortality and generate a high monetary cost for health and social 
care systems [1,2]. The high prevalence of diabetes and increasing incidence in many 
developing countries mean this complication is likely to become more burdensome. 
Across the globe, clinical guidelines for diabetes recommend screening for the risk of foot 
ulceration but individual guidelines vary substantially in the evidence used to support 
recommendations with many based on clinical consensus [3–8]. The consequence of this 
situation is a wide variation in the clinical symptoms, signs and tests that health professionals 
use to identify a person’s risk of foot ulceration. Moreover, because foot risk assessment tools 
are often derived in people at high risk of ulceration [9,10], they may not perform well in 
people whose risk is low. Because some of the recommended tools require expensive 
equipment and clinically time-consuming procedures there is likely to be considerable value 
in the identification of a simple, evidence-based, risk assessment tool with high prognostic 
value. 
Our purpose was to derive and validate a prognostic model of independent risk factors for 
foot ulceration in diabetes using all available individual patient data (IPD) from cohort 
studies conducted worldwide to inform the development of an evidence-based clinical 
prediction rule [11,12]. 
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<H1>Methods 
We undertook a systematic review and meta-analyses of IPD collected in cohort studies of 
predictive factors for foot ulceration in diabetes (PROSPERO no: CRD42011001841). 
Ethical approval was not required because the data were anonymized, already published and 
in the public domain [13,14]. 
Included studies had to recruit people with a diagnosis of diabetes who were free of foot 
ulceration, or whose authors could provide separate data from those who did not have 
ulceration at recruitment. The outcome of interest was foot ulceration. 
<H2>The review eligibility criteria 
People aged 18 years old and over, with a diagnosis of diabetes (Type 1 or Type 2), with at 
least one foot, who were free of ulceration at the time of entry to a cohort study with 
ulceration as the outcome variable. 
<H2>Search strategies 
Electronic searches were conducted in MEDLINE and Embase databases from inception to 
August 2017 (MEDLINE) and June 2017 (Embase). One reviewer applied the review 
eligibility criteria to the full-text articles and a second reviewer checked a 10% random 
sample to ensure that no eligible studies were missed. 
<H2>Quality assessment 
We compiled a list of items relevant to our review question sourced from published quality 
assessment checklists for cohort studies [14]. 
 
<H2>Development of the model
 
Data were cleaned, and extreme values checked with the authors. Where there were missing 
data, discussions to understand the pattern of missingness took place. We included variables 
for which the greatest amount of data from several sources were available. Variables had to 
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have been collected in at least three data sets; be defined consistently across data sets (or be 
able to be recoded) and the extent of heterogeneity should not be so large as to invalidate the 
meta-analysis. 
A univariate logistic regression analysis was performed to obtain odds ratios (ORs) using all 
variables which met our criteria. The ORs were examined in forest plots to assess 
heterogeneity, then those variables thought to be clinically important, biologically plausible, 
and easy to measure in clinical practice were considered by the whole research team. 
For data from a particular study to be included in the model it must have a complete set of 
these variables. There was a trade-off between the number of variables and the number of 
studies that were included, with more variables leading to fewer studies because of lack of 
additional variables in study data sets. 
<H2>Primary statistical analysis 
A multivariable model was fitted using the core variables of the primary model in each 
separate cohort study using logistic regression with first incident foot ulceration as the binary 
outcome. We did not analyse predictors of recurrent ulceration. We adjusted the ORs from 
each study with the same set of predictors [17–19]. These were included in meta-analyses 
using a random effects model by the generic inverse method and heterogeneity was assessed 
using I
2
 and tau-statistics [20]. We conducted the analyses first using patient data from the 
total population regardless of previous history of foot ulceration and a second analysis using 
only data from people with no previous history of foot ulceration to check whether the same 
variables were predictive in both groups. Our approach to a planned survival analysis 
deviated from our published protocol in that we performed a two-step meta-analyses because 
the largest cohort study (n = 6603) [21] had no time-to-ulceration data and another large data 
set (n = 3412) [22] was only available to the project statisticians via a Safe Haven facility and 
could not be physically merged with the other data sets for a one-step approach [23]. 
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To validate the final model an independent statistician re-estimated the ORs in a new data set 
(n =1489) not previously used in our analysis, to allow a comparison of the ORs from our 
meta-analysis [24]. 
We calculated sensitivity, specificity and positive and negative likelihood ratios for an 
inability to feel a 10 g monofilament and/or any absent pedal pulse with ulceration at 1 and 
2 years after the risk assessments took place as these tests survived validation. Finally, we 
calculated these same measures of diagnostic accuracy for the three risk factors that survived 
validation (the above and history of foot ulceration) for foot ulceration at 1 and 2 years. 
Heterogeneity was assessed visually with forest plots but not with I
2
 or tau-statistics because 
these are less reliable with small numbers of studies. Logistic regression and meta-analyses 
were conducted with SAS 9.3 and the meta package in R. Analyses of sensitivity and 
specificity were all conducted using the DiagMeta package in R (https://cran.r-project.org/). 
<H1>Results 
We contacted the principal investigators of 17 studies [22–38] that met the eligibility criteria 
and an agreement to share anonymized data was obtained from 10 [22–24,32–38]. The flow 
of studies throughout the review and the reasons for exclusion can be found in Fig. S1. 
Data from 16 385 people with diabetes were obtained, of these 1221 (7.5%) experienced a 
foot ulcer (Fig. S2). Authors of eight studies made ‘raw’ data available [22,32–38] and data 
from a ninth study were made available via Safe Haven, a data management system with 
secure and restricted access [23]. Finally, a tenth corresponding author was not granted 
permission from his Institutional Review Board to share data [24] but was able to contribute 
to the meta-analysis by subjecting the data from his cohort study to the same analytical 
procedures as all other studies in our meta-analysis to provide estimates of ORs that 
externally validated the final model independently. The characteristics of each individual 
study can be found in Table 1. 
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The percentage of missing data in the studies included in the final model was < 3% (range 0–
2.9%). Eye problems, tuning fork, ankle reflexes, foot deformity, ethnicity, living alone, pin-
prick test, temperature test and peak plantar pressure variables were either not collected in a 
minimum of three studies or were inconsistently measured across studies and it was not 
possible to standardize them. We chose any absent pedal pulse rather than ankle–brachial 
indices as a measure of peripheral vascular disease because more studies collected these data. 
The variables selected for inclusion in the primary model by our international 
multidisciplinary team were: age, sex, duration of diabetes, prior ulceration or amputation, 
any absent dorsalis pedis or posterior tibialis pulse on either foot, and insensitivity to 10 g 
monofilament at any foot site. 
<H2>The primary meta-analysis 
The results of the univariate and primary multivariable model meta-analyses together with 
those from the validation analysis are presented in Tables 2 and 3. Forest plots of the pooled 
ORs with 95% confidence intervals (CIs) are provided for the primary model’s predictors in 
multivariable analyses in Figs 1–3 and S3–S5. The ORs in the multivariable analyses were 
adjusted for age, sex, duration of diabetes, insensitivity to 10 g monofilament, any absent 
pedal pulse, and history of foot ulceration. 
A history of foot ulceration was found to be predictive of diabetes-related foot ulceration. 
This effect was also observed in the analyses of the external data set (Fig. 1) (meta-analyses 
OR 6.59, 95% CI 2.49 to 17.45; validation OR 2.98, 95% CI 2.15 to 4.13). 
The 10 g monofilament test was shown to be consistently predictive in the meta-analyses and 
in the external validation data set (Fig. 2) (meta-analyses OR 3.18, 95% CI 2.65 to 3.82; 
validation OR 3.49, 95% CI 2.49 to 4.89). Notably the estimated heterogeneity was zero. 
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The absence of at least one pedal pulse was shown to be predictive in the meta-analyses and 
the validation data set (Fig. 3) (meta-analyses OR 1.97, 95% CI 1.62 to 2.39; validation OR 
2.56, 95% CI 1.22 to 5.36). 
The duration of diabetes was not found to be consistently predictive between the meta-
analyses of nine studies (Fig. S3) (meta-analyses OR 1.02, 95% 1.01 to 1.04) when compared 
with the analysis of the validation data set (OR 0.98, 95 CI 0.97 to 0.99) 
Age was not found to be predictive of foot ulceration in either the meta-analyses (Fig. S4) or 
the external validation data set (meta-analyses OR 1.00, 95% CI 0.99 to 1.02; validation OR 
0.99, 95% CI 0.98 to 1.01). 
Female sex was found to be protective of foot ulceration across studies in the IPD meta-
analysis (meta-analyses OR 0.74, 95% CI 0.60 to 0.92) (Fig. S5) but this finding was not 
replicated in the validation study, which included mostly men. 
The ORs calculated from meta-analyses of data from people who had never experienced a 
foot ulcer did not differ statistically from the analysis of data from the entire study population 
data except for the variable ‘female sex’ (Table 3). The results for gender were not 
statistically significantly different for people who had no history of ulceration (OR 0.84, 95% 
CI 0.68 to 1.04) but were statistically significantly different in the total population (OR 0.74 
(95% CI 0.60 to 0.92), the latter estimate suggesting female gender is protective of foot 
ulceration in those who have a history of foot ulceration. 
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The calculation of accuracy measures within 1 and 2 years of assessment using the two risk 
factors in combination was only possible in three studies because these had ulcers necessary 
for analyses at 1 and 2 years (n = 1781) [32,33,36]. The estimates of sensitivity, specificity 
and likelihood ratios for a 10 g monofilament test used alone, the absence of any pedal pulse 
used alone and the combined use of a 10 g monofilament test and any absent pedal pulse 
results where one or other of these elements produces a positive result are presented in Table 
4. Heterogeneity in the pooled specificity data makes meta-analyses of these data impractical 
(Figs S6 and S7) hence we report the sensitivities, specificities and likelihood ratios of the 
three studies individually. 
The results from either the 10 g monofilament test or any absent pedal pulse being positive 
were found to increase the sensitivities in each study, ranging from 74.2% to 95.3% at a cost 
to the specificities (specificities ranging from 27.1% to 66.3%), the corresponding positive 
likelihood ratio varied from 1.31 to 2.31 and the negative likelihood ratio from 0.17 to 0.54. 
(Table 4, Figs S8 and S9). 
For each study, no statistically significant differences were found between 1 and 2 years for 
the majority of measures using the monofilament test or any absent pedal pulse alone or 
combined. (Table 4). 
Estimates of sensitivity and specificity from combining all three risk factors increased the 
sensitivity and reduced the specificity of the prognostic model at 1 and 2 years after testing 
(n = 1781). The sensitivity and specificity for a 10 g monofilament test, the absence of any 
pedal pulse and a history of foot ulceration (where any one of the elements produces a 
positive result) are presented in Table 5. 
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Risk assessments with all three risk factors at an interval of 1 year show sensitivities of 
between 90.0% and 95.3%, while the corresponding specificities were reduced to between 
12.1% and 63.8%. Risk assessments at 2-year intervals with the three risk factors in 
combination showed sensitivities between 90.9% and 95.6% with corresponding specificities 
reduced to between 13.2% and 63.9% (Table 5). Any absent pulse was found to be more 
informative than the three-factor model in the population reported by Pham [36]. 
In one study [33], the three-factor model sensitivity exceeded that of the two-factor model by 
a statistically significant degree at 2 years (Tables 4 and 5). In another study [36], the three-
factor model specificity was statistically significantly lower than that of the two-factor model 
at both 1 and 2 years (Tables 4 and 5). 
<H2>Risk of bias 
For the five items used to assess the quality of the conduct of the studies, five studies 
exhibited a low risk of bias [22,32,33,36,38]. However, the collection of outcomes in a 
‘blind’ manner was a feature of only 50% the studies which exposes some of these data to the 
threat of investigator bias. 
<H1>Discussion 
The central importance of foot risk assessment in health checks for people with diabetes is 
acknowledged by healthcare systems across the world. Our analyses, based on data collected 
internationally, indicate that only three risk factors, a history of foot ulceration, the inability 
to feel a 10 g monofilament and the absence of at least one pedal pulse, are required to 
distinguish between those who will ulcerate and those who will not with a high degree of 
accuracy comparable with other, more complex, prognostic models [39]. The simplicity of 
our model has advantages for clinical practice because it is intuitively correct to suppose that 
the fewer tests and elements from the patient history that healthcare professionals are 
required to consider, the more likely risk assessment procedures will be performed. 
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The very large ORs calculated for a history of foot ulceration were perhaps unsurprising and 
there can be no doubt about the high-risk status of these individuals. However, the most 
consistent set of results in the meta-analysis were obtained from data for the 10 g 
monofilament test and this quick, simple and relatively cheap test identified risk in all cohort 
studies with remarkable consistency. The almost complete absence of heterogeneity in the 
meta-analyses of monofilament data came from five studies involving 11 522 people from 
three different countries, and as such was unexpected. 
The results for any absent pedal pulse indicate that this sign is also independently predictive 
of a risk of foot ulceration. Our use of ‘any absent pedal pulse’ as a measure of PVD may 
have underestimated the predictive value of vascular disease for foot ulceration. In a study of 
major vascular outcomes in people with Type 2 diabetes, every additional absent pedal pulse 
resulted in a proportional increase in the hazard ratios [40]. 
Adding the palpation of any absent pedal pulse to an inability to feel a 10 g monofilament 
increases sensitivity at 1- and 2-year intervals. When two and three factors were combined, 
higher levels of sensitivity, but correspondingly lower levels of specificity, were observed. 
This is because any two tests combined with a Boolean OR are bound to increase sensitivity 
at the expense of specificity. Whether this is acceptable depends on the clinical context [41] 
but in this scenario the consequences of failing to detect a person at risk of foot ulceration 
(false negatives) may be potentially far more serious than the increased routine healthcare 
costs associated with false-positive results from a test with lower specificity. The high levels 
of sensitivity for the combined models support the extension of screening intervals beyond 
the conventional 1 year in those who test negative (i.e. do not exhibit either two or three risk 
factors). 
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The variation in the accuracy of the two- and three-factor models in the two smaller studies 
deserves consideration. The heterogeneity in the effects of predictive models can arise from 
differences in disease spectrum, populations, settings, timing and the prevalence of the 
disease or outcome (incidence) [42,43]. The ulcer incidence was higher in two studies 
[33,36], as was the number of re-ulcerations, compared with the population described by 
Crawford (Table 1) [32]. The worse foot pathology of these people may also explain the 
likelihood ratios obtained for these two cohorts which indicate that the informative value of 
the models is low [44]. 
The number of years that a person has had a diagnosis of diabetes was found to be a risk 
factor, but there is a high level of heterogeneity in the meta-analyses and this finding was not 
confirmed in the validation analysis. Female sex seems to confer some protection against 
ulceration and this might relate to a greater propensity for self-care and attention to foot 
health among the women in the study populations [45], or reflect other physiological or 
behavioural differences relating to sex. Sex was not validated as a significant predictor in the 
validation data set, which had a predominantly male population [24]. 
The quality of the conduct of the 10 studies included in the systematic review was assessed as 
high. Only one item was found to threaten the validity of the included studies: the blinding of 
the individuals who ascertained the outcome variable (ulceration) was only maintained in 
50% of the included studies [22,32,33,36,38]. This is widely believed to be an important 
quality factor in prognostic studies and clinical prediction rules [46,47]. However, the meta-
analyses upon which our conclusions are based included only one study [23] in which the 
investigators knew the status of the index test results for some cases and the estimates these 
data contribute only differ statistically from pooled estimates for one prognostic factor – 
previous history of ulceration or amputation. This may result from the inherent difference in 
study design, being the only study to use routinely collected data. 
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<H2>Strength and limitations of the results 
Our externally validated prognostic model for foot ulceration in diabetes used all obtainable 
IPD from global cohort studies and the analysis is based on data from 11 816 people with 
diabetes, the largest of its kind. The differences in the demographics of the included 
populations, the international and clinical settings in which the data were collected and the 
variety of health care professionals who undertook the foot assessments mean the findings 
have good external validity. That our international, multidisciplinary group of individuals 
considered the most clinically useful variables for inclusion in a prognostic model helped 
ensure that all clinical perspectives and expertise were represented. 
The main limitation of the work is that the model results are expressed as summary ORs, 
which do not readily allow clinicians to assess risk and our research is on-going to produce a 
clinical prediction rule with a simple scoring system based on calculated relative risks from a 
sample of these data. From these we plan to produce risk categories and assess the 
performance of the clinical prediction rule by analysing its properties of discrimination and 
calibration [48]. The lack of data for systemic conditions such as stroke or coronary heart 
disease is also a limitation; all three risk factors in our model are intrinsic to the foot and none 
are suitable for self-care. Furthermore, the small number of studies (n = 3) included in the 
analysis of accuracy measures of the model means these estimates of diagnostic accuracy 
should be interpreted with caution. 
<H2>Implications for policy, practice and research 
Given the increased worldwide prevalence in diabetes, a clinical prediction rule based on data 
collected globally and involving only three risk factors that are easy to measure could lead to 
more people with diabetes having foot ulcer risk assessments and improved outcomes. The 
duration of the screening interval should be the focus of future research for this simplified 
prognostic model. 
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<H1>Conclusions 
This systematic review and meta-analysis of IPD collected worldwide has produced a simple 
prognostic model of three risk factors that are independently predictive of foot risk ulceration 
in diabetes. Although an even simpler model appeared more suitable for use in a speciality 
foot clinic, the informative value of re-testing people with a history of foot ulceration is 
questionable. The prognostic utility of a history of foot ulceration, an inability to feel the 10 g 
monofilament and at least one absent pedal pulse indicates that the implementation of such a 
simplified approach to annual diabetes foot checks could reduce the amount of clinical time 
spent testing and thereby permit more people with diabetes to be classified for risk of foot 
ulceration and potentially lead to more effective prevention. 
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